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Abstract 
 
 
Background The pregnancies represent a big physiologic change, although in the majority of 
the cases this alteration are easily exceed, sometimes, associated or not with previous 
pathologies can cause important complication to the pregnant women. The low numbers of 
registered cases hinder then a more specific study on the subject. The aim of this review is 
explore the main causes of sudden death directly and indirectly related with pregnancy. 
Materials and methods Using article databases such as PubMed and books of obstetrics and 
legal medicine and organizations of the last ten years, we collected, and integrated 
information about the etiology of maternal sudden death including definition, 
physiopathology, epidemiology and risk factors, clinic, diagnosis, and autopsy findings. 
Results The last results from Directorate-General of Health in 2013 features a maternal 
mortality of 8 deaths per 100000 live births. Between 2001 and 2007, in Portugal, 21.7% of 
the total number of maternal deaths were of unknown cause.  
The main direct causes are hemorrhage/coagulation disorder, hypertensive disease of 
pregnancy, infection/sepsis and embolism. Pathologies such as heart and neurologic diseases, 
cancer disease and infection are the most important indirect causes.  
Discussion Sudden death in pregnancy has a big impact in the society but actually in Europe 
it has been little explored. 
Conclusion In order to decrease maternal death is essential the establishment of national and 
international reports with updated statistics and awareness of physicians to the importance of 
the implementation of the screening measures and treatment filed for each stage of pregnancy. 
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Introduction 
 
The World Health Organization (WHO) defines Maternal Mortality as the deaths of women 
during pregnancy, childbirth or in the 42 days of puerperium, independent of the duration and 
the local of the pregnancy. The concept of Maternal Mortality includes all the causes that can 
be associated or aggregated with pregnancy or its management. According to this definition, 
ectopic pregnancy and abortion are included in the causes, but the incidental deaths are 
excluded. [3] It is one of the most important indexes of the health care service of a country. [4] 
The last data publish by WHO, in 2015, indicated that Maternal Mortalities are 12 and 239 
per 100000 live births in developed and developing countries respectively. The first one has a 
lifetime risk of maternal death of 1/4900 comparing with the 1/150 in developing countries.( 
table 4) [2] 
The absolute numbers have been decreasing in 44% in the last 25 years, with the 
technological evolution, better access to health care and the reduction of pregnancies in 
extreme ages. [2] 
United Nations created the Millennium Development Goals (MDGs), which include maternal 
death surveillance and response (MDSR) in order to improve the precision of the notification 
of the deaths. The aim of MDSR was to decrease maternal mortality in 75% at 2015. The new 
aim is to get less than 30 deaths per 100000 pregnancies until 2030. [1] Primary prevention is, 
since 2015, a human right and a social concern. [1] 
The current methods used to assess the maternal mortality ratio are very inaccurate and the 
numbers provided are not enough to recognize the major failures in diagnosis and treatment. 
In order to decrease the number of these errors the public health surveillance needs a 
continuous interpretation of actualized data. Reliable data on maternal mortality implies an 
active vigilance, which requires the study of each new case. This would ideally involve an 
autopsy (clinical or forensic) as the circumstances demand. [3] 
 
According to the DGS (Directorate-General of Health), in 2013, which are the last numbers in 
Portugal, maternal mortality is 8 deaths per 100000 live births. [5] This data is based 
fundamentally in clinic elements and in almost every case, the autopsy (clinical and forensic) 
is not included. [5] 
The autopsy results are very important, because there are great discrepancies between the 
publish data and the real causes of death, that only can be confirm with the autopsy. This 
discrepancies became clear in 2008 in United Kingdom when it was performed a study with 
exhaustive evaluation, which included a series of autopsies. Unexpectedly, they realized, 
comparing with other countries, that indirect causes are more prevalent than direct causes. [6] 
In 2009, a study in India proved that the discrepancy between clinical and autopsy diagnosis 
is more than 15%. [3] We believe that it is important to give more attention to the forensic 
study of maternal deaths in Portugal, in order to improve the published data and, therefore, 
defining health policies and be able to decrease the number of deaths. 
The forensic assessment should include the clinical records, macroscopic and microscopic 
findings and toxicology, biochemistry and microbiological analyses. In order to do a complete 
autopsy study, it is important to keep in mind the specific and related pathologies, and some 
pathologies that can get worse with pregnancy. [3] 
In maternal mortality it's known that there are four distinct categories, direct and indirect 
causes, coincidental and late deaths. [5] 
This paper reviews the most recent published articles and the last statistical studies published 
by DGS and WHO, based on maternal mortality and the main direct and indirect death causes 
that can be neglected by doctors, leading to sudden death.  
The aim is to create a review of the main pathologies that can affect pregnancy and to become 
a good tool for health care service, since almost every cause is preventable. 
Therefore, we approach the definition, physiopathology, epidemiology and risk factors, clinic, 
diagnosis, and autopsy findings of each one. This work also aims to understand the role of the 
autopsy in sudden death during pregnancy and its possible contribution to the improvement of 
health care.  
 
Materials and methods  
 
Using article databases such as PubMed and books of obstetrics and legal medicine and 
organizations of the last ten years, we collected and integrated information about the etiology 
of maternal sudden death including the definition, physiopathology, epidemiology and risk 
factors, clinic, diagnosis, and autopsy findings Maternal mortality can be divided into to four 
categories, direct causes, indirect causes, coincidental and late deaths. 
 
 
 
1) Maternal deaths directly related to pregnancy 
 
Maternal deaths directly related to pregnancy include all deaths caused by obstetric 
problems.[7] The most frequent direct causes of maternal mortality are thrombosis and 
thromboembolism, pre-eclampsia and eclampsia, hemorrhagic disorders, amniotic fluid 
embolism and sepsis. [7] 
 
1.1) Thrombosis and thromboembolism  
 
Thromboembolism (VTE) is the combination of two pathologies: deep venous thrombosis 
(DVT), which is a condition caused by the formation of clots in the deep veins, usually in the 
lower limbs (deep veins of the legs or in the pelvic veins, like the uterine veins); and 
pulmonary embolism, which is defined by the obstruction of  lung arteries caused by clots. [8]   
In the antepartum period, the pathopysiology of VTE can be explained by: (a) the venous 
stasis caused by the progesterone-induced venodilatation, pelvic venous compression by 
gravid uterus and pulsatil compression of the left and right iliac veins, (b) hypercoagulability 
associated with increased thrombin production, and (c) fibrinolysis reduction due to the 
increased plasminogen activator inhibitor type 1 and 2 activity and decreased tissue 
plasminogen activator activity.[8] [9] 
In postpartum period, the vascular damage to the pelvic vessels that can occur after normal 
vaginal, assisted vaginal or cesarean section deliveries, and postpartum move restriction are 
the main alteration in the pathophysiology of VTE during the postpartum period. The 
hypercoagulability starts to decrease in the postpartum period and the risk gradually return to 
basal.[9] 
 
Embolism is one of the main causes of death in pregnant woman with an estimated risk of 
0,8-4,7 per 100000 maternities.[9] The highest risk of thrombosis starts with pregnancy and 
lasts until about two months after delivery.[8] The main risk factors to VTE are: obese 
pregnancy, above 35 years old, sedentary life and caesarean delivery (rather than vaginal 
delivery) and coagulation mutations like the factor V Leiden.[7] [8] [10] 
 
The presence of symptoms like breathlessness, syncope, pleuritic pain, cough and 
hemoptysis, accompanied by the presence of signs like tachypnea, tachycardia and cyanosis 
should arise attention of the medicine assistant to the possibility of VTE.[10] 
The diagnosis of VTE is difficult to execute and normally only 10% have a final diagnosis. 
D-Dimers test, ultrasound, Doppler ultrasound, computed-tomography (CT), magnetic 
resonance (MR) or venography, are the most important support methods of the diagnosis.[11] 
The American Thoracic society and the society of Thoracic Radiology have proposed an 
algorithm for the diagnosis of pulmonary embolism. This algorithm included CT pulmonary 
angiography, ventilation-perfusion scintigraphy, MR angiography and intravascular 
pulmonary angiography. [11] 
The review of the societies guidelines about thromboembolism prophylaxis (The American 
Congress of Obstetricians and Gynecologists, 2015; The American College of Chest 
Physicians, 2015 and The Royal College of Obstetricians and Gynecologists, 2015) shows 
that there is a significant difference between each others guidelines, but, even with an amount 
of studies conducted, they concluded that the thromboembolism risk during delivery has 
increased in the last years. They justify it with an inadequate risk assessment, inadequate 
thromboprophylaxis, failure to investigate symptoms, and failure to ensure multidisciplinary 
care. [12] [13] 
 
In cases of sudden death, if the autopsy is performed, it is necessary to check thrombus in the 
main pulmonary arteries to confirm the diagnostic of pulmonary thromboembolism. It is also 
important to confirm that the embolism was the cause of death and not a postmortem event. [8] 
Then it is required the research of the thrombus origin which is made by dissecting the deep 
veins of the legs and the pelvic veins. [8] 
 
 
Hypertensive syndromes remain the leading causes of maternal morbidity and mortality. 
These syndromes have pathological consequences in the normal liver function. [14] 
The hypertension-related liver disease during pregnancy includes pre-eclampsia (PE), 
eclampsia (E), heamolysis, elevated liver enzymes, low platelets syndrome (HELLP) and 
acute fatty liver of pregnancy (AFLP). [14] 
 
 
 
 
1.2) Preeclampsia and eclampsia 
 
Pre-eclampsia (PE) is an hypertensive syndrome characterized by hypertension 
(>140/90mmHg) plus proteinuria (upper urinary excretion to 0.3g of protein in a 24-hour 
urine sample) after the 20th week.[8] 
PE can be allocated into two categories, early and late PE.  Although the etiology of this 
pathology is yet unknown, the main hypothesis in early PE cases is an alteration on the 
normal implantation of the placenta [8] which includes the presence of an incomplete and 
imperfect invasion of the spiral arteries into the trophoblast during the implantation. [15] [16] [17] 
The later PE is related with an enlarged placental mass or surface. It can occur in cases of 
pregnant women with diabetes, nulliparous pregnant, anemia or in high altitudes. [17] 
The hypertension has major systemic repercussions, the most important of which is in the 
cardiovascular (increased in blood pressure and in cardiac output) and in hematological 
system (risk of hypovolemic shock, thrombocytopenia and disseminated intravascular 
coagulopathy (DIC)). [15] Placental abruption, HELLP syndrome, thromboembolism and 
pulmonary edema, are some examples of the complications caused by hypertension progress. 
[18] 
 
Eclampsia (E) is an evolution of PE, with major neurologic changes like convulsions and 
coma, when other causes, such as epilepsy, are excluded. [8] 
Hypertensive syndromes (PE, E, HELLP syndrome) affect 2-8% of the pregnant women. 
Nulliparous pregnant, extreme age groups and family history have an higher risk of 
developing PE. Higher risks are also associated with systemic lupus, diabetes and chronic 
hypertension.[6] 
 
Typical signs and symptoms of hypertensive syndromes are: headache, epigastric pain, visual 
alterations, oliguria or anuria, hepatocellular dysfunction and hyperreflexia.[16] 
During pregnancy, the diagnosis can be done by periodically measuring the blood pressure 
and the proteinuria (screened with 24-hours urine test).[8] The symptomatology, the presence 
of high blood pressure (140/90 mmHg) [11] and upper urinary excretion to 0.3g of protein in a 
24-hour urine sample, make the diagnosis of pre-eclampsia. [8] Nowadays, some studies about 
the substitution of 24-hours urine collection for the 12-hours test show an advantage of 
convenience and improved clinical efficiency (of the later). Furthermore, there are 
investigations in order to implement some biomarkers in the first and second semesters to 
prevent this syndrome from de beginning. For the first semester it is proposed Placental 
Growth Factor (PIGF) and in the second semester the Human Chorionic Gonadotrophin 
([hCG]>2.0 MoM) and Associated Plasma Protein-A ([PAPPA]<5th centile). These 
biomarkers seem to have more accuracy to predict pre-eclampsia. The importance of these 
new biomarkers is the need for early start of tracing PE. Nowadays this prevention only starts 
in the mid to the end of the second trimester and the dysfunction of the placenta may already 
be establish. [17] [19] 
The large discordance between the cutoff of the different studies is the greatest obstacle to the 
progress in prevention and early diagnosis of hypertensive syndromes.[17] 
 
PE kills 3 women per day, this remains as one of the most frequent causes of death in 
pregnant women. In the case of sudden death the main findings at autopsy are a soft liver 
parenchyma with associated hematoma or a large haemoperitoneum caused by the liver 
capsule's rupture especially the right lobe (liver rupture).[7] The microscopic section shows 
edematous changes in fibrinoid material, and recent blood extravasation.[8] A third of the 
cadavers present brain alterations, with subcortical edema, vascular lesion consistent with 
fibrinoid necrosis of arterial walls, perivascular infarction and hemorrhage within the white 
matter, basal ganglia and pons or even a ventricular rupture can be present.[11] 
 
 
 
1.3) HELLP syndrome  
 
The HELLP syndrome is characterized by hemolysis (consequent of a microangiopathic 
hemolytic anemia (MAHA)), elevated liver enzymes and decreased platelet concentration 
(<100.109/L). [20]  
 
This syndrome is classified as a severe variant of the PE and it occurs in about 5 to 10% of 
pregnant women with severe PE [8]  with a frequency of 0,2-0,6% during pregnancy.[14] The 
peak of incidence is between 27 and 37 weeks and until 48 hours after delivery.[20] Contrary to 
PE, the risk factors are multiparous pregnant women, caucasian and older than 35 years old 
women.[16] In a posterior pregnancy the risk of recurrence is 20%. [20] 
 
The main symptom of HELLP syndrome is an upper right quadrant pain or epigastric pain, 
that worsens overnight and can be associated with nauseas and vomiting. These symptoms 
usually progress continuously but the intensity can change spontaneously. [20] 
The diagnosis include laboratory analysis with platelets count under <100.109/L and an 
increased concentration of liver enzymes (AST, ALAT). The last analysis, often reflects the 
presence of hemolytic processes. Although the increased levels of α-GST and GST-a1 are the 
most sensitive factors to appoint acute liver injury, they cannot be used in diagnosis yet. [20] 
HELLP syndrome have a maternal mortality of 3,4-24,2 %. [21] The autopsy findings are 
similar to preeclampsia. [8] 
 
 
1.4) Acute fatty liver of pregnancy 
 
Although still poorly elucidated, the main hypothesis to explain this condition is the 
deficiency of the long-chain 3-hydroxyl-CoA dehydrogenase. [8] This alteration interferes in 
the fatty acid degradation through beta oxidation in hepatic mitochondria. [14] 
 
Acute fatty liver of pregnancy is a potentially fatal condition but it is very rare with an 
incidence of 1 per 10000 pregnant women. [3, 8, 14, 16] It occurs most frequently in the third 
trimester and the differential diagnosis with other hypertensive syndromes can be difficult. [16] 
 
The first symptoms related with this pathology are headache, nausea, vomiting, abdominal or 
focalized right upper quadrant pain, itching and confusion, which lead the pregnant women to 
the hospital. [11] 
The diagnosis is difficult and normally the first diagnostic hypothesis are PE or hepatitis. 
Although biopsy is rarely done due to the large risk to the pregnancy, it is the only way to 
confirm the diagnosis. Imagiological exams like ultrasound and magnetic resonance have low 
sensibility. That’s why the presumed diagnosis is done by the clinical and laboratory findings 
(elevation in the transaminase, direct bilirubin, and uric acid levels, anemia normocytic 
normochromic and leukocytosis)[16] 
 
The major complications and causes of death in pregnant women, with acute fatty liver, are 
renal failure, DIC and sepsis. [16] At autopsy, it is possible to check a fatty liver.[8] The 
diagnosis is microscopically confirmed with the presence of microvascular centrilobular 
steatosis, cholestasis, cytoplasmic ballooning, inflammation and necrosis of hepatocytes. [8] 
 
 
 
 
Obstetrical hemorrhage continues along with infections and hypertension to constitute the 
famous triad responsible for the majority of cases of death in pregnant women. The 
decreasing maternal mortality rate related with hemorrhagic causes has as been achieved in 
recent years and that represents a great global maternal mortalities decrease. 
         1.5) Hemorrhage  
 
1.5.1) Hemorrhagic stroke 
 
Hemorrhagic stroke (HS) incidence has been increasing lately. It is subdivided in 
subarachnoid hemorrhage (SAH) and intracerebral hemorrhage (ICH). The SAH results, more 
frequently (approximately 80%), from a cerebrovascular alteration or a saccular aneurysm 
rupture. [11, 22] In a lower percentage, SAH can be a consequence of a coagulopathy, 
angiopathy, venous thrombosis, infection, drug abuse, cancer or trauma. [11] The ICH is caused 
by a rupture of a small vessel previously damage by chronic hypertension. [11]  
Although a stroke is uncommon during pregnancy or the postpartum period, a venous 
infarction thrombosis of dural sinuses can cause it. It has a multifactorial etiology including 
hypercoagulable state typical of pregnancy, protein S deficiency and dehydration. [8] 
 
HS has a prevalence of 6 per 100000 deliveries.[22]The advanced age (above 35 years old), 
arterial hypertension, pregnant woman medicated with anticoagulants, antiplatelet and 
fibrinolytic drugs, alcoholism and the presence of arteriovenous malformations are the major 
risk factors recognized. [8] During the postpartum period the risk of SAH increase.[8] 
 
The major symptoms and signs are headache, vomiting and local neurologic deficits. [8] The 
diagnosis of this condition implies a large index of suspicion by the clinician. A lot of 
pregnant women enters the emergency service with few classic risk factors of HS or only with 
a slight increase of the blood pressure.[22] Imagiologic exams after suspicious clinical findings 
are the best way to determine the diagnosis of SAH.[8] 
 
The mortality percentage of SAH and ICH are 10% and 20% respectively.[22] At autopsy it is 
possible to evaluate the presence of hematoma. Microscopic section may present vascular 
malformations or other vascular disease, infection findings, cancer and other possible 
etiologies. [8] The autopsy can confirm the presence of thrombosis in the dural sinuses.[8] 
 
 
1.5.2) Haemoperitoneum 
 
Facing haemoperitoneum the clinician should consider a uterine rupture, ruptured subcapsular 
hematoma, aneurysm rupture of the splenic artery, ectopic pregnancy, placenta previa, 
placenta increate and abruption placentae. [8] 
a) Ectopic pregnancy  
 
Ectopic pregnancy is the implantation of the blastocyst outside the endometrial lining of the 
uterine cavity. This occurs in consequence of the anatomic or functional obstruction, impair 
tubular motility, ciliary dysfunction and molecular chemotactic factors that stimulates and 
protects tubular implantation. [23] 
Although this is a rare cause of maternal death, is still the primordial cause in the first 
trimester due to hemorrhage and infection, with a prevalence of 20 per 1000 pregnancies. [16] 
The most frequent location is in the fallopian tubes (98%). [8] [16] 
Genital and pelvic infections are risk factors of ectopic pregnancy, as the use of medically 
assisted reproduction techniques, tobacco, scar of previous surgery and age above 35 years 
old. [16] 
 
A pregnant woman may have an acute or subacute symptomatology. The most common 
presentation is a woman with a menstrual delay, positive pregnant test, abdominal-pelvic 
pain, metrorrhagia and hypovolemic shock. [8] More than 50% of the pregnant women with 
ectopic pregnant have at least a risk factor. [23] 
The diagnosis of this pathology includes reunion of clinical findings, transvaginal ultrasound 
and B-HCG (>1000IU/L) dosing. [23] If the diagnosis is not clear, an exploratory laparoscopy 
can be done. [8]  
A tubal ectopic pregnancy location can result in tubal abortion, tubal rupture or spontaneous 
resolution.[15] 
 
At autopsy it's possible to observe the ectopic localization and the haemoperitoneum in case 
of rupture. [8] 
 
 
b) Uterine rupture 
 
The uterine rupture (UR) is a disruption of the uterine wall that can be total or partial. [8] UR 
can be traumatic or non-traumatic. 
UR has a prevalence of 1 per 100 deliveries to 1 per 1850 deliveries.[8] In non-traumatic cases, 
the risk factors are previous caesarean section, increased gestational age, multiparity and the 
use of uterotonic drugs (like oxytocin and prostaglandins). Uterine rupture can occur during 
an obstetric intervention as mid-forceps delivery and prolonged labor with cephalopelvic 
disruption. [8] The traumatic uterine rupture is due, in most of the cases, to road accidents. [8] 
 
In the beginning of pregnancy, women may have an acute abdomen frame with intense pain 
and signs of internal bleeding. With the advance of pregnancy, the patient may be 
asymptomatic or only presenting a slight abdominal pain or vaginal bleeding. During labor, 
the rupture is felt with a strong localized pain in the abdomen. [16] 
The diagnosis is based on clinical history and physical examination. In case of doubt, it is 
possible to resort to an ultrasound to confirm the diagnosis. [16] 
 
In the autopsy it's possible to observe the haemoperitoneum and the rupture of the uterine 
wall. [8] 
 
 
c)   Placenta implantations 
 
The placental previa (PP) is defined as a low implantation of the placenta that obstruct totally 
or partially the internal os. Low-lying placenta is defined as a low implantation localized at 
least two centimeters of the internal os. [11] 
PP is an important cause of bleeding during the 3th trimester of pregnancy and delivery. This 
pathology has a prevalence of 3 to 5 per 1000 deliveries. [24] [20]  The major risk factors are 
multifetal gestation, age above 35 years old, previous cesarean section, cigarette smoking and 
an increase in perinatal screening of maternal serum Alfa- fetoprotein. [11] 
The most typical and frequent sign is a moderate painless vaginal bleeding. [11] 
The diagnosis is made by ultrasound or MR, allowing verification of the placenta position.  [16] 
In the autopsy it's possible to confirm the wrong position of the placenta. [8] 
 
The excessive invasion of the myometrium by the placenta is called accreta. Different degrees 
of invasion have different classifications (accrete, increte, precreta). The accrete placenta is 
the main cause of intractable postpartum hemorrhage and emergency hysterectomy 
intrapartum. [24]  
The defect of the decidua with an imperfect fibrinoid or Nitabuch layer and the alteration of 
cytotrophoblasts, that can control the decidua invasion through the control of angiogenesis 
and growth factors, represent the major alteration in this pathology. [11] 
The incidence of accretism is 1 per 533 deliveries. Throughout time it was discovered a 
correlation between increte placenta and placenta previa, previous uterine curettage, previous 
cesarean section, multiparity and advanced maternal age (above 35 years-old).[24]  
Typically, pregnant women resort to emergency service with vaginal hemorrhage that may 
appear only in the third trimester. [11] 
Although the diagnosis can be made by Doppler ultrasonography and MR imaging, when a 
pregnant woman is asymptomatic (absence of vaginal bleeding) these tests are less 
sensitive.[24] 
The accrete placenta represents 8% of the deaths related with hemorrhage. In autopsy, the 
anatomopathologic diagnosis of accretism is made by histological study with the presence of 
trophoblastic islands in myometrium. [8] 
 
The abrupt placenta (AP) is the separation, total or partial, of the placenta from the local of 
implantation.  AP begins with hemorrhage to the decidua that then split, leaving a thin layer 
adherent to the myometrium. The etiology can be an impaired trophoblastic invasion with 
subsequent atherosis. Other possibility can be inflammation or infection of the 
myometrium.[11] 
The prevalence is 4 to 35 per 1000 deliveries.[25] AP can be a cause of dangerous bleeding in 
addition to the risk of intrauterine death.[20, 24] This injury can be caused by a traumatic 
event or it may have a non-traumatic cause like maternal hypertension, cigarette smoking and 
cocaine abuse.[8] 
The main symptoms and signs are abdominal pain and abdominal tenderness. The shock can 
manifest within few minutes or hours after the injury .[8, 24]  
The diagnosis is based on clinical history and physical examination and supported by some 
imaging tests such as ultrasound and MR.[8, 25] In the initial phase pregnant women can be 
asymptomatic, if there isn't more abruption of the placenta, the diagnosis can only be made 
after delivery when assessing the placenta, when the clinician verifies an area few centimeters 
wide with a dark surface  and with blood clots. [11] 
At autopsy, the placenta must be verified in order to find signals of abruption like dark 
surface and the presence of blood clots. The presence of cocaine in the blood and the presence 
of signs of trauma should be analyzed too. [8] 
 
d) Ruptured aneurysm of the splenic artery  
 
The ruptured aneurysm of the splenic artery is more common in the third trimester of 
pregnancy and this pathology has an high mortality rate. The main causes are unknown, but 
the main hypotheses are hemodynamic and hormonal (increase in the estrogens and 
progesterone concentrations) alteration during pregnancy, uterus compression and the 
increase in the arteries flow. [26] 
The increase in estrogens and progesterone concentration can have as consequence the 
disruption of the internal elastic lamina, fragmentation of the elastic fibers, degeneration of 
smooth muscle fibers, and failure of elastin formation. The relaxation can be increased too 
and that may affect the elasticity of the splenic artery wall. [26] 
The majority of this aneurysms are saccular, located 2-5 cm from the splenic hilum. [8] The 
prevalence is between 0,01 and 10,4 %. The multiparity, portal hypertension, atherosclerosis 
and medial fibrodisplasy increase the risk of this pathology. [26] 
 
Pregnant females who have this condition may be asymptomatic (when the aneurysm has less 
than 2 cm in the major diameter or they can present an epigastric pain with or without signs of 
shock. [27] The diagnosis has improved recently due to the evolution and use of imaging 
studies as angiography, the MR and CT.[27] 
 
The mortality of the ruptured aneurysm of the splenic artery is around 75%. [28] At the 
autopsy, it can be very difficult to identify the aneurysm. It is important to careful dissect the 
full length of the splenic artery. [8] 
 
 
 
 
Amniotic fluid embolism (AFE) is a rare cause of sudden death in pregnant women, but, it is 
considered by many, as a key factor. [29] Mortality has decreased by raising awareness as a 
condition that can become catastrophic. [29] 
 
1.6) Amniotic fluid embolism  
 
Despite the lack of information, it is thought that the main cause of AFE is related to 
immunology, where an idiosyncratic reaction is triggered by the access of amniotic fluid to 
the maternal circulation. This access implies failure in the physical barriers in utero-placental 
unit (e.g. Endocervical veins). [29] Recurrence risk is very low.[29] The coagulopathy occurs as 
a result of both procoagulant and anticoagulant factors and it's likely to be multifactorial. [29] 
 
The incidence, 7 to 8 per 100000 births, is still somewhat vague due to the different types of 
methodology used in studies and the low number of studies. [29] [8] [30] 
The major risk factors are the changes in the barriers (e.g., placental abruption) or increased 
intrauterine pressure (e.g., uterine contractions), maternal age above 35 years old, multiple 
pregnancy, cesarean section, assisted delivery or eclampsia. [29] 
 
Clinical signs related with AFE are hypotension, fetal distress, pulmonary edema or ARDS, 
cardiopulmonary arrest, cyanosis and coagulopathy. However, the clinical presentation 
usually has a great diversity of sings and symptoms.[29] 
Diagnosis is based on four inclusion criteria (1) the acute hypotension or cardiac arrest; (2) 
acute hypoxia; (3) severe coagulopathy with clinical bleeding in the absence of other 
explanations; (4) an event during delivery, cesarean delivery, surgery to the uterus or within a 
period of postpartum and defined by no other explanation for the results. [29] Imaging study 
can give some contribution to the diagnosis, but there is no specific test.[29] 
The diagnostic can be achieved by demonstrating the presence of squamous cells of the fetus 
in maternal blood, through the introduction of a catheter into the pulmonary artery. [8] 
Clinical suspicion, traditional laboratory data, or intravascular cellular debris (demonstrated 
only in 50% of patients) are insufficient to make a definitive diagnosis of AFE.  Nowadays, 
biomarkers capable to confirm the diagnosis are inexistent. Modern biomarkers may help 
differentiate AFE from other conditions.[30] 
The highest levels of STN (Sialyl Tn), an fetal antigen present in meconium and amniotic 
fluid, which is an high sensitivity test used, were found in AFE non-survivors and can be the 
key for predicting the severity and mortality of AFE. [29] 
 
The main consequences of this pathology are heart failure and DIC. [31] In cases of sudden 
death it's hard to find the failure of the barrier. [8] The autopsy diagnosis is made by 
histological studies with the detection of fetal products in the maternal pulmonary arteries, 
like squamous epithelial cell, meconium, lanugo and mucins (origin in the intestinal tract of 
the fetus). The difference between fetal cells and maternal squamous cell shedding is made by 
the presence of nuclei in the maternal peeling endothelial cells, which normally does not 
appear in fetal squamous cells. [8] We can still do immunohistochemical staining with 
cytokeratin that mark the squamous cells but not the endothelial ones. Mucins are usually 
present but it is hard to detect because they rarely stain with routine dyes. However it's 
possible to stain with "Alcian blue" or mucins staining. It is sometimes possible to find 
products of amniotic fluid in the uterine and cervical veins. [8] 
 
 
 
Sepsis remains a leading cause of maternal death, in contrast with what was expected, the 
maternal sepsis has increased even in developed countries. [32] 
 
 
 
1.7) Sepsis  
 
Nowadays the main scientific societies have different definitions for the classification of 
sepsis. This fact makes the compression of this pathology even harder. [32] 
WHO, in 1992, defined puerperal sepsis as an infection of the genital tract occurring at any 
time between the rupture of membranes or labour and the 42 days in the postpartum period. 
Two or more of the following symptoms are present: pelvic pain, fever, abnormal vaginal 
discharge and delay in the reduction of the size of the uterus. [33] 
ICD-10 (International Classification of Diseases) defines puerperal sepsis as an higher 
temperature of 38°C continued for 24h or recurrent during the period between the end of the 
first day and the end of the tenth day after birth. [32] 
In 2002, a surviving sepsis campaign defined systemic inflammatory response syndrome 
(SIRS) as a widespread inflammatory process caused by an infection, trauma, thermic lesion 
or sterile inflammatory process. It requires the presence of two of the criteria: (a) temperature 
<36ºC or >38º C, (b) frequency cardiac >90 bpm, (c) respiratory frequency>20cpm and (d) 
leukocytes <4 x1010 cells per liter or> 12x 109 cells per liter.[7] 
The surviving sepsis campaign defined sepsis as a SRIS associated with an infection. [32] 
Severe sepsis presents hypotension and hypoperfusion, which responds to fluid resuscitation, 
and organ dysfunction. And finally septic shock is the worst state of sepsis without fluid 
resuscitation response[7]. 
Sepsis may have an obstetric or non-obstetric etiology. Obstetric causes include septic 
abortion, chorioamnionitis, perineal infection, endometritis, surgical wound infection and 
puerperal mastitis. The non-obstetric causes included urinary infection, respiratory infection, 
appendicitis, pancreatitis, hepatitis, malaria and infection by the human immunodeficiency 
virus (HIV), among others. [32] 
Between all this causes, pyelonephritis, chorioamnionitis and endometritis are the most 
important causes of septic shock in pregnancy and postpartum period. [32] 
 
An american study, conducted between 1998 and 2008, showed a sepsis incidence of 1 per 
17246 births. The most frequent risk factors depend on the infection agent, host factors and 
pregnancy and delivery factors.[32] 
Anemia, obesity, previous caesarean section, premature rupture of membranes, diabetes 
mellitus or glucose intolerance, immunosuppression, tobacco, maternal age above 35 years 
old, chronic diseases and low socio-economic stratum are included in the host factors. [32] 
The main agents related with maternal death are streptococcus group A beta-hemolytic and 
Escherichia coli. The first agent exists in 5-30% of the population as an asymptomatic way. [7] 
 
The main clinical findings are fever or hypothermia, tachycardia, tachypnea, hypoxia, 
hypotension, oliguria and state of consciousness. [32] The diagnostic is done by the clinical 
findings, a blood culture and C-reactive protein. The signals and symptoms can be subtle due 
to the physiological adaptation of the pregnancy. [32] 
Blood cultures should be made in the source of infection such as vaginal, respiratory secrecies 
or cerebrospinal fluid before the introduction of antibiotics. Imaging scan like chest x-ray, 
ultrasound and computer tomography may help the diagnosis.[7] 
 
Sepsis in pregnant women can result in increased preterm birth rate, hypoxia, acidosis, 
stillbirth and fetal infections.[34] 
Puerperal sepsis has worldwide mortality of 15%. The recent increase in maternal deaths in 
developed countries can be justified with (a) the advanced maternal age, obesity, 
cardiovascular disease, chronic renal diseases, erythematosus systemic lupus and smoking; 
(b) household childbirth; (c) increased number of infections by Streptococcus beta Group A 
beta-hemolytic and Escherichia coli; (d) the use of assisted reproductive techniques, invasive 
prenatal diagnostic test, and caesarean delivery [32]. An antibiotic prophylaxis can reduce the 
incidence of sepsis and, consequently, the incidence of maternal deaths. [32] 
Sepsis rarely is the primary diagnosis. Normally the objective of the autopsy is to demonstrate 
a concomitant disease, which may have been neglected. The best interval to do the autopsy is 
in the first 15 hours after death and the acquisition of some clinical information is 
fundamental before starting the post-mortem exam. [35] 
Sampling may change from situation to situation but the more extensive and varied it is, the 
possibility to do the diagnosis and determine the starting point of the infection increases. [35] 
Examples include sampling of blood, organs product aspiration, cerebrospinal fluid, urine and 
feces. The culture of these products is still very effective, however, nowadays other exams 
including DNA technique like PCR supported by immunohistochemistry can facilitate the 
diagnosis. [35] 
 
 
2) Maternal deaths indirectly related to pregnancy 
 
Maternal deaths indirectly related to pregnancy include all deaths caused by the 
intensification of a disease that already existed prior to pregnancy.[7] 
The cardiac diseases are causing more deaths in recent years. It includes some examples like 
peripartum cardiomyopathy, aortic dissection, arrhythmogenic right ventricular 
cardiomyopathy among others. Central Nervous System (CNS) disorders most frequent are 
intracerebral hemorrhage, cerebral thrombosis and epilepsy.[7] 
Also included respiratory diseases (e.g. asthma), endocrine, metabolic and immunologic 
diseases (e.g. diabetes), gastrointestinal system diseases (e.g. pancreatitis), blood disorders 
(e.g. thrombotic microangiopathy), circulatory system diseases, kidney and tumors (e.g. 
pheochromocytoma).[7] 
The HIV or bacterial infections prior to pregnancy are also indirect causes. [7] 
 
 
2.1Cardiac disease  
 
The cardiac disease in pregnant women may be one of the main indirect causes of sudden 
death. [7] This pathology has a prevalence of 2,31 per 100000 pregnancies.[7] The main risk 
factors are obesity, tobacco and hypertension.[7] 
The etiology can be congenital (pulmonary hypertension and cardiac congenital diseases) or 
acquired (ischemic and non-ischemic). [7] 
The acquired non-ischemic conditions include the aortic dissection, peripartum 
cardiomyopathy, myocarditis, arrythmogenic right ventricular cardiomyopathy, among 
others.[8] [7] 
 
 
 
2.1.1) Peripartum cardiomyopathy 
 
Peripartum cardiomyopathy (PC) etiology, like most of the disorders during pregnancy, is still 
under research.[8] The main hypothesis for PC is a fetal autoimmunity and microchimenism, 
myocarditis and the dietary excess of salt or deficiency of selenium. PC is marked by the 
development of systolic heart failure.[36] 
PC can have an hereditary and genetic component.[36] The most recent studies propose a 
truncating variants as a strong genetic predisposition. [36] 
This cardiomyopathy it's more frequent in the last month of pregnancy until 6 months after 
birth, with the peak of incidence in the second month after delivery.[8] 
The incidence of this pathology is 1 per 1000 or 4000 births.[8] [36] PC is more frequent in 
black pregnant women, age above 35 years old, multiparous, preeclampsia and 
hypertension.[7] 
 
Pregnant women with this condition usually present dyspnea, edema, orthopnea, tachypnea 
and tachycardia.[7] The diagnosis is made with a chest x-ray and an echocardiogram. They 
should be accompanied by a specialist and possibly included in the regional transplant 
center.[7] In US, PC represents 4% of all cardiac transplants. [36]   
 
PC has a mortality of 5 to 10%, and it is a rare cause of maternal sudden death. [36]  The most 
frequent mechanisms of death are attributed to arrhythmia or thromboembolism. [8] At autopsy 
there are nonspecific findings as enlarge heart, dilated cardiomyopathy, irregular myofibrils 
and fibrosis, and variable myocardium T cell infiltration. [7]7] [8]  
 
 
2.1.2) Arrhythmogenic right ventricular cardiomyopathy 
 
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited disease in which 
50% of the cases with autosomal dominant transmission. ARVC is characterized by fibro-
fatty changes of the right ventricle, ventricular arrhythmia, and sudden death.[37]  
Although this ARVC is normally considered a pathology of desmosomes, in fact only 50% of 
the cases have mutations in the genes of this component. Recent studies in mice showed 
changes in signaling via Rho-kinase, which is implicated in the regulation of intracellular 
transport and cytoskeletal filament organization, that supports the desmosomal complex 
proteins in cell-cell junctions in the myocardium. Mice that had Rho-kinase inhibition 
exhibited spontaneously developments of cardiac dilatation and dysfunction, fibro-fatty 
change and ventricular arrhythmia that resulted in premature death of the mice. This pattern 
corresponds with ARVC in humans. [37] 
 Ventricular tachycardia is provoked by hemodynamic changes of pregnancy, as the increased 
in the cardiac output or anemia when associated with prior cardiac pathology.[38] [39] 
This pathology has an incidence of 1:5000 births.[38]   
 
This disease has a ranging spectrum of presentation, from asymptomatic to sudden death.  
Usually pregnant woman presents with palpitations and syncope. The diagnosis is made by 
electrocardiogram, classically with a left bundle-branch block that can be accompanied by 
inversion of the T wave from V1 to V3 and premature ventricular complexes. [38]  Nowadays 
the availability of genetics tests increases the early recognition of ARVD.[38] 
 
In the autopsy it's possible to evaluate the fibrous-adipocyte tissue replacement myocardium, 
although it is not pathognomonic. Normally there is attenuation of myocytes, transversal 
stretch marks and areas with less myofibrils, this alteration gives the appearance of "bubbly". 
[40] 
 
2.1.3) Aortic dissection  
 
Acute aortic dissection (AAD) is a rare phenomenon during pregnancy despite a well-
established risk relationship. [41] AAD is characterized by a rupture of the intimal layer of the 
aorta with blood extravasation, forming a subintimal hematoma that produces a false double-
channel effect. [41]  It has an incidence of 1,39 cases per 100,000 person/year among pregnant 
women under 40, compared to 0.4 cases per 100,000 person/year in pregnant women aged 
between 15 and 45. [41] [7] As previously mentioned, pregnancy is a risk factor, which is 
increased with gestational hypertension, preeclampsia, Marfan and Ehlers-Danlos syndrome. 
 
Pregnant women with sudden and persistent thoracic and interscapular pain should lead to an 
AAD diagnosis that can be done by Trans-esophageal echocardiography, a CT scan or an 
MRI. [7] [41]  
 
AAD can complicate with aortic valve insufficiency, avulsion of the carotid arteries resulting 
in myocardial infarction or stroke. [41] This pathology represents 3-14% of maternal cardiac 
death. [41] 
In autopsy it is possible to observe hemothorax and a rupture of the aortic or coronary 
artery.[8] Microscopically it's possible to confirm the recent artery dissection with the 
underlying aortic medial degeneration. Because Marfan and Ehlers-Danlos syndromes are 
both great enhancers of aortic dissection as in global population as in pregnant women, 
genetic testing for these syndromes should be done. [41] [7] 
 
 
2.1.4) Cardiac ischemia and myocardial infarction 
 
Nowadays, myocardial infarction is one of the most frequent causes of pregnant cardiac death 
(20%). The etiology can be variable like atherosclerosis, coronary dissection, or even an 
autoimmune disease.[7]  
In more than 25% of the cases the main etiology is coronary dissection, most frequent in the 
left descendent anterior artery, in the anterior wall (78%).[42]  The coronary dissection is more 
frequent in the postpartum period and it is possibly a result of the hemodynamic and 
hormonal changes during pregnancy. In young pregnant women the most frequent etiology is 
embolic and normally with classic risk factors but with the presence of structural cardiac 
diseases.[42] 
Coronary spasm and dissection can be consequent of drug abuse (e.g. cocaine). [42]  
The prevalence of cardiac ischemia (CI) is 6.2 per 100.000 pregnancies [43] CI is more 
frequent during the third trimester and six weeks following the deliver. [43]The risks factors 
are obesity, tobacco, age above 35 years old, more than 3 births, diabetes, hypertension, 
thrombophilia and family story. [7] [43] Pregnancy increases three or four times the risk of a 
CI.[43]In pregnant women, and because the etiology is rarely atherosclerosis, the symptoms 
can be very different. The most frequent ones are abdominal or epigastric pain associated by 
vomiting and dizziness. [7] 
 
The diagnosis is made by a serial of parameters that include the symptomatology, 
electrocardiogram (ECG) and the study of the cardiac enzymes (like troponin). A normal 
ECG does not exclude the diagnosis. In order to overtake this problem, women should do 
various ECG. The study of coronary arteries is also necessary trough a coronary angiogram 
with angioplasty with or without stenting. [7] 
 
At autopsy it is possible to evaluate the typical macroscopic and histological changes of a 
myocardial infarction and also explore the etiology. In the majority of the cases, it's possible 
to find atheroma plaques in the coronary arteries or a dissection of the same arteries.[7] 
 
 
2.2) CNS (central nervous system) 
 
2.2.1) Epilepsy 
 
Sudden death in epilepsy (SUDEP) is defined, in pregnant population as in general 
population, as: "death, unexpected, witnessed or unwitnessed, non-traumatic and without the 
patient drowning due to epilepsy, with or without evidence of a seizure and excluding the 
documented epilepticus status, where autopsy did not reveal a toxicological or anatomical 
cause of death." [44] 
The physiologic alteration during the pregnancy, such as the increase in the progesterone and 
estrogen and the alteration in the absorption, distribution, metabolism and elimination of the 
antiepileptic drugs, is the main hypothesis for the negative impact of epilepsy. [45] 
In many countries such as the UK, studies have concluded that the mortality rate increases 10 
times during pregnancy in women with epilepsy when compared to women without the 
disease.[44] The prevalence of epilepsy in pregnancy is 0.61 to 1 per 100,000 births. [7] The 
major risk factors of SUDEP in a pregnant woman are chronic epilepsy with poorly controlled 
seizures, hyperventilation, sleep privation, stress, physical pain and lack of compliance with 
medication.[46] 
 
Sometimes it is difficult to diagnose epilepsy during pregnancy due to the proximity of clinic 
sings typical of pregnancy. Headaches, changes in mood, dizziness, confusion and memory 
loss are some of the most common symptoms.[46] The diagnosis of epilepsy is mainly clinical 
but there are auxiliary diagnostic tests such as EEG, CT and MR that can help.[47] 
Guidelines recommend to prevent SUDEP (a) choose the optimal treatment before 
conception, (b) prefer monotherapeutic approach if possible, (c) opt for the most efficient 
AED according to the type and frequency of seizures, (d) begin with the lowest effective dose, 
and (e) not forget folic acid supplementation. [45] 
 
In autopsy of SUDEP cases it's possible to find alterations in several organs including (a) 
brain (edema and hypoxia signs), (b) heart (fibrosis driver system), (c) lungs (increased 
weight and pulmonary edema with alveolar hemorrhage and exudate) and finally the (d) liver 
(increased venous congestion and weight which are cardiac failure signals).[48] 
 
 
 
2.3) Blood flow 
 
2.3.1) Thrombotic microangiopathy 
 
Thrombotic microangiopathy include primary disease like thrombotic thrombocytopenic 
purpura (TTP) and hemolytic uremic syndrome.[8]  
TTP characterized by the presence of microthrombi rich in vWF and the presence of 
ADAMTS13 inhibitors in the blood. [49] Normally, it arises before of 24 weeks. 
The prevalence of this pathology is 1 per 25000 to 1 per 100000 pregnancies. [50] 
 
Most frequent symptoms and signs are neurological (lethargy, seizures, mental confusion), 
fever, kidney dysfunction, severe thrombocytopenia (gingival, gastrointestinal or genital 
bleedings, bruises, petechial), abdominal pain, diarrhea, anemia, intravascular hemolysis, 
visual disturbance and cardiac dysfunction by thrombotic events in the microcirculation.[16]  
In the case of pregnant women who have already TTP prior the pregnancy it's normal the 
worsening of the situation. Unfortunately, in many cases it is necessary to terminate 
pregnancy before fetal viability.[16] 
 
The absence of pathognomonic laboratory data hampers the diagnosis. Identification of 
ADAMTS-13 deficiency is helpful to allow specific care of this potentially fatal disease. 
When the diagnosis is done in postpartum period, the maternal prognosis is reserved. [16] 
Lactic deshidrogenase (LDH) is always very high due to hemolysis. [16] 
 
TTP is a disease with a mortality rate higher than 60% when untreated and although it is not a 
specific disease of pregnancy, this pathology can be trigger by it. [49] In cases of sudden death, 
at autopsy the conditions that cause the formation of widespread microthrombi are called 
thrombotic microangiopathy of pregnancy. [8] 
 
 
2.4) Tumors 
 
2.4.1) Pheochromocytoma 
 
Pheochromocytoma is a cromaphin tissue tumor located, in 80-85% of cases, in the adrenal 
glands  and, in 15-20% of the cases, in extra-adrenal sites (for example Zuckerkandl body) 
characterized by increased release of catecholamines. [51] [52] This tumor typically known as 
"10% tumor" because it is 10% bilateral, 10% multiple, 10% hereditary and 10% 
malignant.[51] 
 It is extremely rare in pregnant women, with an incidence of 1 per 50,000 pregnancies. [51]  
 
Clinically the main symptoms are headache, hypertension, hyperhidrosis, and heart 
palpitations.[51] [52]  
In pregnant women, despite the absence of screening tests, it is recommended to carry out 
biochemical tests, measurements in blood and urine catecholamine metabolites levels 
(metanephrine and Normetanephrine) when in presence of a sustained or paroxysmal 
hypertension, clinical signs of increased secretion of catecholamines or when they have a 
family history of pheochromocytoma. [51] [52] 
When biochemical tests have positive results, the second phase of diagnosis is achieved by 
undertaking imaging tests to locate the tumor. [51] 
 
The risk of sudden death in pregnant women with pheochromocytoma is due to paroxysmal 
hypertension and hypotension that may be precipitated by vaginal delivery, the fetal 
movements, abdominal palpation, uterine contraction, bleeding or general anesthesia.[52] 
Vaginal delivery has been contraindicated in the past but is acceptable nowadays if the patient 
is stable. [52] 
The mechanism of death normally is necrosis of the tumor produced by the compression of 
the gravitic uterus that leads to a cardiopulmonary failure by the extensive liberation of  
catecholamines.[51] 
 At autopsy it's possible to find a mass in the adrenal gland that it is formed in the medulla 
layer. [51, 53] Macroscopic analysis demonstrate a necrotic and hemorrhagic mass. In 
microscopic analysis it's possible to confirm the endocrine origin with the presence of 
polygonal cell with low number of granules and acidophilic cytoplasm, decentered nucleus 
fusiform and round elements that suggest anisocytoses, as well the disposition of the cell over 
rows conjunctive and vascular tissue with an anarchic orientation.[51] 
 
 
Discussion and conclusions 
 
Sudden death in pregnancy has a major impact in the society, but actually in Portugal, as in 
many other countries, it has been poorly explored. 
 
In 2007, DGS published a report about the main causes of maternal mortality. Although these 
datas have more than 8 years, these were the last numbers presented in Portugal. [54] This 
publication includes maternal mortality (MM) (figure 1), ratio of maternal mortality (RMM) 
(Table 1), the maternal death by age groups (Table 2) and the main causes of maternal 
mortality (Table 3). [54] 
The most frequent causes are cardiac disease such as, pulmonary hypertension, cardiac 
congenital disease, aortic dissection, peripartum cardiomyopathy, myocarditis, right 
ventricular arrhythmogenic cardiomyopathy, and ischemic disease. [7, 54] A percentage of 
21,7% of the maternal death had unknown cause. [54] 
 
In 2015, DGS publish a report with the most important health index, whose maternal 
mortality was included. This report show the datas of 2013, with a maternal mortality of 8 
deaths per 100000 live births.[5] 
 
The last data publish by the WHO, in 2015, indicated that Maternal Mortalities are 12 and 
239 per 100000 live births in developed and developing countries respectivel.[2] With this data 
we can concluded that Portugal is below of the mean of the developed countries, even so, the 
importance of the reduction of this numbers is crucial. 
 
Nowadays knowledge, allows the prevention of the majority of deaths, but failures in diverse 
points turn it not a reality yet. Failure to detect signs or symptoms and the late feature of the 
pregnant women to medical cares are actually the two most important causes of maternal 
death. [55] [56] Although it is important to review the services provided to every pregnant, it is 
also important understand the various barriers that stand between pregnant woman and these 
services. The difficulty in transport to medical facilities, low educational level and economic 
problems are some of the obstacles for the preventive measures come evenly to all pregnant 
women.[57] 
Since all pregnant women, and especially those who have high risk from the beginning, are at 
risk of suffering complications that can lead to her death, it is important to implement 
measures that allow uniform access to maternal health care from the start and more intense in 
the third trimester as we already been mentioned, is the time when the risk of death 
increases.[55]  
 
The production of more recent reports that specifically show the current numbers of each 
cause of maternal death and the number of case that the etiology remained unknown is 
actually very important to understand the reality of our country in order to actualized our 
guidelines in the routine of the pregnancy vigilance and to create better access to the health 
care for the pregnant woman. So, to complete this reports it’s very important that each case is 
study individually and, in the end, all cases have a definitive diagnosis of the cause of death. 
The diagnosis can be made by the clinical with de clinic symptoms, sings and auxiliary test. If 
the clinician has doubts about the pathology, it is possible to accomplish a clinic autopsy. On 
the other hand, if there are some clinical doubts it’s necessary to perform a medical legal 
autopsy. The pos-mortem study should be standardized in order to avoid misclassification and 
loss of information.[7] A study based on anatomo-pathological findings is a good possibility to 
better understand the real weight of each cause of maternal deaths around the world. 
 
During the research, we realized that the majority of the diseases that appear during 
pregnancy are still understudied, the few scientific studies that have so far been allowed in 
pregnant women were not enough to understand the etiology, pathogenesis and even to test 
some therapeutic specifically in this stage of woman's life. Only in some diseases, like 
hypertension syndromes, hemorrhage and infection, there is a well-established prevention 
methodology. Surviving sepsis campaign, as others campaigns, had a good impact in death 
reduction in non-pregnant women due to establishing guidelines, standardized treatment and 
greater investment in training of health professionals. Perhaps it is time to apply this strategy 
to pregnant women. 
 
In order to compare the situation of Portugal with other European countries, we researched 
their respective reports and we realize that, like Portugal they weren’t updated for many 
years. [58] [59] A Swedish study shows a pregnancy related mortality ratio of 7.3 which is  64% 
highest than the report of World Health Organization.[58] But just as Portugal, the Swedish 
report is from 2007. [58] 
The Spaniards report includes statistic numbers between 2001 and 2005 show a RMM of 4.1 
and a increase in 20% of the number of pregnant woman with 35 years or over since 1996. [59] 
 
United Nations created, in 2000, the Millennium Development Goals (MDGs), which include 
maternal death surveillance and response (MDSR) in order to improve the precision of the 
notification of the deaths. The aim of MDSR is to get less than 30 deaths per 100000 
pregnancies until 2030. [1]  
 
In each hour, 30 women die around the world from pregnancy complications. Some of 
maternal death can be avoided with better individual heath cares so it is very important to 
prioritize the health politics and funding programs to achieve better data on maternal 
mortality and thus improve the health indices.[55] 
 
Although it still has a long way to go, MRSD studies are the beginning for a new era with a 
more accurate view of this major problem that is maternal mortality. Review on this subject 
allows saving the lives of many pregnant women and their newborns. 			
References: 
 
 
1. Tara M Herrick, C.M.H.-J., Alice M Levisay, et al, Prioritizing investments in innovations to 
protect women from the leading causes of maternal death. BMC Pregnancy and Childbirth, 
2014. 14. 
2. WHO, U., UNFPA, World Bank Group and the United Nations Population Division, Trends 
in maternal mortality: 1990 to 2015 Estimates by WHO, UNICEF, UNFPA, World Bank 
Group and the United Nations Population Division. 2015. p. 12. 
3. Sharma, B.R.e.a., Forensic considerations of pregnancy-related maternal deaths: An 
overview. ournal of Forensic and Legal Medicine 2009. 16(2009): p. 233-238. 
4. Belizán, S.M.a.J.M., The true cost of maternal death: individual tragedy impacts family, 
community and nations, B. central, Editor. 2015. 
5. Principais Indicadores da Saúde para Portugal 2015, DGS. p. 1. 
6. S, L., Maternal Death, Autopsy Studies, and Lessons from Pathology. . PLoS Med, 2008. 2(5): 
p. e48. 
7. Roch Cantwell, T.C., Griselda Cooper, Andrew Dawson, James Drife MD, Debbie, Garrod 
RM, Ann Harper Saving Mothers’ Lives: Reviewing maternal deaths to make motherhood 
safer—2006–08. Vol. 118. 2011. 205. 
8. David Dolinak , E.M., Emma Lew, Forensic Pathology: Principles and Practice. 1st ed. 616. 
9. Roger, M., Pregnancy and venous thromboembolism: ´TIPPS` for risk stratification. 2014, 
American Society of Hematology: Reprodutive Reasoning: Hematology and Reprodution. p. 
387-392. 
10. Cavalcanti, E.F.d.A.M., Herlon Saraiva., Clínica médica: dos sinais e sintomas ao diagnóstico 
e tratamento. . 2007: p. 1958. 
11. F. Cunningham, K.L., S. Bloom, et al, Williams OBSTETRICS. 24th ed. 2014. 
12. Alexander M. Friedman, M.C.V.A., PhD et al, Thromboembolism incidence and prophylaxis 
during vaginal delivery hospitalizations. American Journal of Obstetrics & Gynecology, 
2015. 221: p. e1- e12. 
13. Alexander M. Friedman, M.C.V.A., PhD Obstetrical venous thromboembolism: Epidemiology 
and strategies for prophylaxis. Elsevier, 2015. 0(0). 
14. Kenya Kamimura, H.A., Hirokazu Kawai et al, Advances in understanding and treating liver 
diseases during pregnancy: A review. World J Gastroenterol, 2015. 21(17): p. 5183-5190. 
15. Charles R. B. Beckmann, F.W.e.a., Obstetrics and Gynecology. 6ª ed. 497. 
16. Graça, L.M.D., Medicina Materbo-Fetal. 4ª ed. 
17. Yan Zhong, F.Z.a.Y.D., Serum screening in first trimester to predict pre-eclampsia, small for 
gestational age and preterm delivery: systematic review and meta-analysis. BMC Pregnancy 
and Childbirth, 2015. 15: p. 191. 
18. Alex R. Souza, M.R.A., Aurélio A. R. Costa, Carlos N. Neto, Tratamento anti-hipertensivo na 
gravidez Acta Med Portuguesa, 2010. 23: p. 077-084. 
19. Stout MJ1, C.S., Colditz GA, et al, The Utility of 12-Hour Urine Collection for the Diagnosis 
of Preeclampsia: A Systematic Review and Meta-analysis. Obstet Gynecol, 2015. 126(4): p. 
731-736. 
20. Haram, K.S., E. Abildgaard, U., The HELLP syndrome: clinical issues and management. A 
Review. BMC Pregnancy Childbirth, 2009. 9: p. 8. 
21. De Oliveira, R., De Matos, IC., Da Silva, TBP et al, Síndrome Hellp: estudo de revisão para o 
cuidado de enfermagem Enfermaria global, 2012. 28: p. 346-354. 
22. Lisa R. Leffert, M.C.R.C., B et al, Patient Characteristics and Outcomes After Hemorrhagic 
Stroke in Pregnancy. Circulation Cardiovascular Quality and Outcomes, 2015. 8(6): p. S170-
178. 
23. Florin-Andrei Taran, K.-O.K., Markus Hübner et al, The Diagnosis and Treatment of Ectopic 
Pregnancy. Deutsches Ärzteblatt International, 2015. 37(4): p. 693-704. 
24. Vyshka, G.C., N. Shaqiri, E., Placenta increta causing hemoperitoneum in the 26th week of 
pregnancy: a case report. J Med Case Rep, 2010. 4: p. 412. 
25. al, F.R.C.R.M.Y.N.T.R.S.M.e., Fetal death in placental abruption: comparison of two 
different time periods. Revista da Associação Médica Brasileira, 2008. 54. 
26. Theodoros Pavlis, C.S., Stavros Gourgiotis et al, Spontaneous Rupture of Splenic Artery 
Aneurysm during the First Trimester of Pregnancy: Report of an Extremely Rare Case and 
Review of the Literature. Hindawi Publishing Corporation, 2012. Obstetrics and 
Gynecology: p. 3. 
27. Betal, D., et al., Spontaneous ruptured splenic artery aneurysm: a case report. Cases J, 2009. 
2: p. 7150. 
28. Veluppillai C, P.S., de Kerviler B et al Splenic arterial aneurysm and pregnancy: A review. 
Presse Med, 2015. 44(10): p. 991-994. 
29. McDonnell, N.J., V. Percival, and M.J. Paech, Amniotic fluid embolism: a leading cause of 
maternal death yet still a medical conundrum. Int J Obstet Anesth, 2013. 22(4): p. 329-36. 
30. Balinger KJ, C.L.M., Hon HH, et al, Amniotic fluid embolism: despite progress, challenges 
remain. Curr Opin Obstet Gynecol, 2015. 27(6): p. 398- 405. 
31. Rosalinda Rodrigues, F.N., Manuel Meirinho  Embolia de liquido amniótico. Acta Medica 
Portuguesa, 2007. 20: p. 93-96. 
32. Rita Torres, N.M., Sara Valadares et al, Maternal sepsis. Acta Obstet Ginecol Port, 2015. 
9(1): p. 65-72. 
33. Buddeberg BS, A.W., Puerperal sepsis in the 21st century: progress, new challenges and the 
situation worldwide. Postgrad Med J, 2015. 91: p. 572-578. 
34. Ricardo Luiz Cordioli, E.C., Romulo Negrini, et al, Sepsis and pregnancy: do we know how to 
treat this situation? Rev Bras Ter Intensiva, 2013. 25(4): p. 334-344. 
35. Tsokos, M., Pathology of Sepsis, in Essentials of Autopsy Practice, G. Rutty, Editor. 2006, 
Springer London. p. 39-85. 
36. James S. Ware, P.D., Jian Li, Ph.D., Erica Mazaika, et al, Shared Genetic Predisposition in 
Peripartum and Dilated Cardiomyopathies. The NEW ENGLAND JORNAL of MEDICINE, 
2016. 
37. Ellawindy A, S.K., Sunamura S, et al, Rho-Kinase Inhibition During Early Cardiac 
Development Causes Arrhythmogenic Right Ventricular Cardiomyopathy in Mice. 
Arterioscler Thromb Vasc Biol, 2015. 35(10). 
38. Agir, A.B., S. Celikyurt, U. Argan, O. Yilmaz, I. Karauzum, K. Vural, A., Arrhythmogenic 
right ventricular cardiomyopathy in pregnancy. Int Heart J, 2014. 55(4): p. 372-6. 
39. Sebastien P.J. Krul, J.J.v.d.S., et al, Systematic review of pregnancy in women with inherited 
cardiomyopathies. European Journal of Heart Failure 2011. 13: p. 584-594. 
40. Allen Patrick Burke, M.C.E.A.P.B., MD, Arrhythmogenic Right Ventricular Cardiomyopathy 
Pathology. 2015: Medsape. 
41. S., S., Spontaneous rupture of acute ascending aortic dissection in a young pregnant woman: 
a sudden unexpected death. Forensic Sci Int., 2013: p. e5-8. 
42. Hind N. Moussa, M.M.M., MD Mateo G. Leon, MD et al, Acute Myocardial Infarction Due to 
Coronary Artery Dissection in the Postpartum Period. Am J Perinatol, 2015. 05(02): p. e93-
e96. 
43. Samanta Soares, Â.F., Ivone Lobo, et al, Acute myocardial infarction in pregnancy – case 
report. Acta Obstet Ginecol Port 2010. 4(4): p. 213-216. 
44. Edey, S.M., N. Nashef, L., SUDEP and epilepsy-related mortality in pregnancy. Epilepsia, 
2014. 55(7): p. e72-4. 
45. Ozhan Ozdemir, M.E.S., Aslihan Kurt,, Pregnancy outcome of 149 pregnancies in women 
with epilepsy: Experience from a tertiary care hospital. Interventional Medicine & Applied 
Science, 2015. 7(3): p. 108-113. 
46. The American Pregnancy Association.  [cited 2015 28.11]; Available from: http://americanpregnancy.org/about/. 
47. Neurolis: clinica de neurologia e neurofisiologia. Lda.  [cited 2015 28.11]; Available from: http://www.neurolis.pt/index.php/epilepsia/diagnostico-da-epilepsia. 
48. Shahin Nouri, M.C.E.S.R.B., MD Sudden Unexpected Death in Epilepsy. 2013: Medscape. 
49. Yamamoto, T.F., Y. Emoto, Y. et al, Autopsy case of sudden maternal death from thrombotic 
thrombocytopenic purpura. J Obstet Gynaecol Res, 2013. 39(1): p. 351-4. 
50. Carpenter, M.R.a.S.L., Thrombotic Microangiopathies. ISRN Hematology, 2012. 2012: p. 8. 
51. Plu, I., et al., Pregnancy, cesarean, and pheochromocytoma: a case report and literature 
review. J Forensic Sci, 2013. 58(4): p. 1075-9. 
52. Cecchi R, F.P., Capri O, Cipolloni L., A rare case of sudden death due to hypotension during 
cesarean section in a woman suffering from pheochromocytoma and neurofibromatosis. J 
Forensic Sci., 2013. 6: p. 1636-9. 
53. J. G. Hudsmith, C.E.T., D. A. Browne, Undiagnosed phaeochromocytoma mimicking severe 
preeclampsia in a pregnant woman at term. International Journal of Obstetric Anesthesia, 
2006. 15: p. 240-254. 
54. Gomes, M.T.V.M.d.C., Mortes Maternas em Portugal, 2001‐2007. 2009, DGS. p. 32. 
55. Steven L. Clark, M.M.A.B., el al, Maternal death in the 21st century: causes, prevention, and 
relationship to cesarean delivery. American Journal of Obstetrics & Gynecology, 2008: p. 36. 
e1- e5. 
56. Tsokos, C.B.M.S.M., Maternal and pregnancy-related death: causes and frequencies in an 
autopsy study population. Forensic Sci Med Pathol, 2013. 9(3): p. 296-307. 
57. Lewis, G., Reviewing maternal deaths to make pregnancy safer. Best Practice & Research 
Clinical Obstetrics and Gynaecology, 2008. 22: p. 447-463. 
58. Esscher, A.H., U. Haglund, B. et al, Maternal mortality in Sweden 1988-2007: more deaths 
than officially reported. Acta Obstet Gynecol Scand, 2013. 92(1): p. 40-6. 
59. Luque Fernandez, M.A.C., A. B. Dramaix-Wilmet, M. et al, Increase in maternal mortality 
associated with change in the reproductive pattern in Spain: 1996-2005. J Epidemiol 
Community Health, 2009. 63(6): p. 433-8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 	
 
 
 
 
		
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Number of maternal deaths (MM), live births (NV) and MMR between 1993 and 2007 in Portugal 
(adapted from Directorate-General of Health) [54] 									
AGE 2001 2002 2003 2004 2005 2006 2007 TOTAL % 
15-19    1 1 1 1 4 4,3 
20-24 2 1 2 1    6 6,5 
25-29 2 4 2 3  4 1 16 17,4 
30-34 2 6 5 4 3 9 2 31 33,7 
35-39 6 3  3 2 5 7 26 28,3 
40-44 2 1 1 2  1  7 7,6 
>44 1   1    2 2,2 
TOTAL 15 15 10 15 6 20 11 92 100,0 
Table 2- Maternal mortality by age group between 2001 and 2007 (adapted from Directorate-General of 
Health) [54] 													
ANO MM NV RMM 
1993 10 114030 8,8 
1994 12 109287 11,0 
1995 9 107184 8,41 
1996 8 110363 7,2 
1997 14 113047 12,4 
1998 6 113510 5,3 
1999 6 116038 5,2 
2000 3 120071 2,5 
2001 15 112825 13,3 
2002 15 114456 13,1 
2003 10 112589 8,9 
2004 15 109356 13,7 
2005 6 109457 5,5 
2006 20 105514 19,0 
2007 11 102567 10,7 
Causes of 
maternal death 2001 2002 2003 2004 2005 2006 2007 TOTAL 
% Of total 
of known 
causes 
Direct        52 72,2 
Haemorrhage/ 
coagulopathy 6 1 1 2 2 4 3 19 26,4 
Hypertensive 
syndrome of 
pregnancy 
3 4 2   7 1 17 23,6 
Infection/ sepsis 1  1 3  1 1 7 9,7 
Tromboembolis  1 1  3  1 6 8,3 
Others embolis     1 1 1 3 4,2 
Indirect        18 25,0 
Infection  1 1  2  4  5,6 
Cardiac death 2 1 1 1  1  6 8,3 
Cancer 1 1      2 2,8 
CNS  1    1  2 2,8 
Others  1  1  2  4 5,6 
Accidental/ 
incidental        2 2,8 
Accidental/suicide    1   1  2,8 
Complete with 
known causes 13 11 7 8 6 19 8 72 100,0 
Unknown 2 4 3 7  1 3 20 21,7 
TOTAL 15 15 10 15 6 20 11 92  
Table 3- Causes of maternal death between 2001 and 2007(adapted from Directorate-General of Health) [54] 									
		
Years	
Figure 1. Evolution of MMR, number of maternal deaths per 100,000 live births between 1975 and 
2007(adapted from Directorate-General of Health) [54] 					
MDG region MMR 
Range of MMR 
uncertainty (80% UI) 
 
Lower            Upper          
Number of 
maternal 
deaths 
Lifetime 
risk of 
maternal 
death 1 in: 
World 216 207 249 303000 180 
Developed regions 12 11 14 1700 4900 
Developing regions 239 229 275 302000 150 
Northern africa 70 56 92 3100 450 
Sub-saharan africa 546 511 652 201000 36 
Easten asia 27 23 33 4800 2300 
Eastern asia excluding china 43 24 86 378 1500 
Southern asia 176 153 216 66000 210 
Southern asia excluding india 180 147 249 21000 190 
South- eastern asia 110 95 142 13000 380 
Western asia 91 73 125 4700 360 
Caucasus and central asia 33 27 45 610 1100 
Latin america and the caribbean 67 64 77 7300 670 
Latin america 60 57 66 6600 760 
Caribbean 175 130 265 1300 250 
Oceania 187 95 381 500 150 
Table 4- estimates of maternal mortality ratio( MMR, maternal deaths per 100000 live births), number of matenal 
deaths, and lifetime risk, by National Millennium Development Goal ( MDG) region, 2015(adapted from WHO) 
[2] 		
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• Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a
low number of pixels and limited set of colors;
• Supply files that are too low in resolution;
• Submit graphics that are disproportionately large for the content.
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Where illustrations must include recognisable individuals, living or dead and of whatever age, great
care must be taken to ensure that consent for publication has been given. It is the authors'
responsibility to obtain written permission to reproduce borrowed material (illustrations and tables)
from the original publishers and authors.
Color artwork
Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or
MS Office files) and with the correct resolution. If, together with your accepted article, you submit
usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear
in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations
are reproduced in color in the printed version. For color reproduction in print, you will receive
information regarding the costs from Elsevier after receipt of your accepted article. Please
indicate your preference for color: in print or online only. For further information on the preparation
of electronic artwork, please see https://www.elsevier.com/artworkinstructions.
Illustration services
Elsevier's WebShop (http://webshop.elsevier.com/illustrationservices) offers Illustration Services
to authors preparing to submit a manuscript but concerned about the quality of the images
accompanying their article. Elsevier's expert illustrators can produce scientific, technical and medical-
style images, as well as a full range of charts, tables and graphs. Image 'polishing' is also available,
where our illustrators take your image(s) and improve them to a professional standard. Please visit
the website to find out more.
Tables
Please submit tables as editable text and not as images. Tables can be placed either next to the
relevant text in the article, or on separate page(s) at the end. Number tables consecutively in
accordance with their appearance in the text and place any table notes below the table body. Be
sparing in the use of tables and ensure that the data presented in them do not duplicate results
described elsewhere in the article. Please avoid using vertical rules.
Web references
Refrain from using online references if possible. When referring to internet sources, for example
Wikipedia, please state so clearly, and indicate if this information can be checked and on which date
you visited this online source.
Reference management software
Most Elsevier journals have their reference template available in many of the
most popular reference management software products. These include all products
that support Citation Style Language styles (http://citationstyles.org), such as Mendeley
(http://www.mendeley.com/features/reference-manager) and Zotero (https://www.zotero.org/), as
well as EndNote (http://endnote.com/downloads/styles). Using the word processor plug-ins from
these products, authors only need to select the appropriate journal template when preparing their
article, after which citations and bibliographies will be automatically formatted in the journal's style.
If no template is yet available for this journal, please follow the format of the sample references and
citations as shown in this Guide.
Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following
link:
http://open.mendeley.com/use-citation-style/journal-of-forensic-and-legal-medicine
When preparing your manuscript, you will then be able to select this style using the Mendeley plug-
ins for Microsoft Word or LibreOffice.
Reference style
Text: Indicate references by superscript numbers in the text. The actual authors can be referred to,
but the reference number(s) must always be given.
List: Number the references in the list in the order in which they appear in the text.
Examples:
Reference to a journal publication:
1. Van der Geer J, Hanraads JAJ, Lupton RA. The art of writing a scientific article. J Sci Commun
2010;163:51–9.
Reference to a book:
2. Strunk Jr W, White EB. The elements of style. 4th ed. New York: Longman; 2000.
Reference to a chapter in an edited book:
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3. Mettam GR, Adams LB. How to prepare an electronic version of your article. In: Jones BS, Smith
RZ, editors. Introduction to the electronic age, New York: E-Publishing Inc; 2009, p. 281–304.
Note shortened form for last page number. e.g., 51–9, and that for more than 6 authors the first
6 should be listed followed by 'et al.' For further details you are referred to 'Uniform Requirements
for Manuscripts submitted to Biomedical Journals' (J Am Med Assoc 1997;277:927–34) (see also
http://www.nlm.nih.gov/bsd/uniform_requirements.html).
Video data
Elsevier accepts video material and animation sequences to support and enhance your scientific
research. Authors who have video or animation files that they wish to submit with their article are
strongly encouraged to include links to these within the body of the article. This can be done in the
same way as a figure or table by referring to the video or animation content and noting in the body
text where it should be placed. All submitted files should be properly labeled so that they directly
relate to the video file's content. In order to ensure that your video or animation material is directly
usable, please provide the files in one of our recommended file formats with a preferred maximum
size of 150 MB. Video and animation files supplied will be published online in the electronic version
of your article in Elsevier Web products, including ScienceDirect: http://www.sciencedirect.com.
Please supply 'stills' with your files: you can choose any frame from the video or animation or
make a separate image. These will be used instead of standard icons and will personalize the
link to your video data. For more detailed instructions please visit our video instruction pages at
https://www.elsevier.com/artworkinstructions. Note: since video and animation cannot be embedded
in the print version of the journal, please provide text for both the electronic and the print version
for the portions of the article that refer to this content.
AudioSlides
The journal encourages authors to create an AudioSlides presentation with their published article.
AudioSlides are brief, webinar-style presentations that are shown next to the online article on
ScienceDirect. This gives authors the opportunity to summarize their research in their own words and
to help readers understand what the paper is about. More information and examples are available at
https://www.elsevier.com/audioslides. Authors of this journal will automatically receive an invitation
e-mail to create an AudioSlides presentation after acceptance of their paper.
Supplementary material
Supplementary material can support and enhance your scientific research. Supplementary files
offer the author additional possibilities to publish supporting applications, high-resolution images,
background datasets, sound clips and more. Please note that such items are published online exactly
as they are submitted; there is no typesetting involved (supplementary data supplied as an Excel
file or as a PowerPoint slide will appear as such online). Please submit the material together with the
article and supply a concise and descriptive caption for each file. If you wish to make any changes to
supplementary data during any stage of the process, then please make sure to provide an updated
file, and do not annotate any corrections on a previous version. Please also make sure to switch
off the 'Track Changes' option in any Microsoft Office files as these will appear in the published
supplementary file(s). For more detailed instructions please visit our artwork instruction pages at
https://www.elsevier.com/artworkinstructions.
Submission checklist
The following list will be useful during the final checking of an article prior to sending it to the journal
for review. Please consult this Guide for Authors for further details of any item.
Ensure that the following items are present:
One author has been designated as the corresponding author with contact details:
• E-mail address
• Full postal address
All necessary files have been uploaded, and contain:
• Keywords
• All figure captions
• All tables (including title, description, footnotes)
Further considerations
• Manuscript has been 'spell-checked' and 'grammar-checked'
• References are in the correct format for this journal
• All references mentioned in the Reference list are cited in the text, and vice versa
• Permission has been obtained for use of copyrighted material from other sources (including the
Internet)
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Printed version of figures (if applicable) in color or black-and-white
• Indicate clearly whether or not color or black-and-white in print is required.
For any further information please visit our customer support site at http://support.elsevier.com.
Submission of figures, tables and captions
Please note: Figures and their corresponding captions can be submitted together in a single file within
EES. Tables and their corresponding captions can also be submitted together in a single file within
EES. Please select the appropriate option(s) in the submission items drop down list.
AFTER ACCEPTANCE
Availability of accepted article
This journal makes articles available online as soon as possible after acceptance. This concerns the
accepted article (both in HTML and PDF format), which has not yet been copyedited, typeset or
proofread. A Digital Object Identifier (DOI) is allocated, thereby making it fully citable and searchable
by title, author name(s) and the full text. The article's PDF also carries a disclaimer stating that it is
an unedited article. Subsequent production stages will simply replace this version.
Use of the Digital Object Identifier
The Digital Object Identifier (DOI) may be used to cite and link to electronic documents. The DOI
consists of a unique alpha-numeric character string which is assigned to a document by the publisher
upon the initial electronic publication. The assigned DOI never changes. Therefore, it is an ideal
medium for citing a document, particularly 'Articles in press' because they have not yet received their
full bibliographic information. Example of a correctly given DOI (in URL format; here an article in the
journal Physics Letters B):
http://dx.doi.org/10.1016/j.physletb.2010.09.059
When you use a DOI to create links to documents on the web, the DOIs are guaranteed never to
change.
Online proof correction
Corresponding authors will receive an e-mail with a link to our online proofing system, allowing
annotation and correction of proofs online. The environment is similar to MS Word: in addition to
editing text, you can also comment on figures/tables and answer questions from the Copy Editor.
Web-based proofing provides a faster and less error-prone process by allowing you to directly type
your corrections, eliminating the potential introduction of errors.
If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions
for proofing will be given in the e-mail we send to authors, including alternative methods to the online
version and PDF.
We will do everything possible to get your article published quickly and accurately. Please use this
proof only for checking the typesetting, editing, completeness and correctness of the text, tables and
figures. Significant changes to the article as accepted for publication will only be considered at this
stage with permission from the Editor. It is important to ensure that all corrections are sent back
to us in one communication. Please check carefully before replying, as inclusion of any subsequent
corrections cannot be guaranteed. Proofreading is solely your responsibility.
Offprints
The corresponding author, at no cost, will be provided with 25 free paper offprints, or,
alternatively, a personalized link providing 50 days free access to the final published
version of the article on ScienceDirect. This link can also be used for sharing via
email and social networks. For an extra charge, more paper offprints can be ordered
via the offprint order form which is sent once the article is accepted for publication.
Both corresponding and co-authors may order offprints at any time via Elsevier's WebShop
(http://webshop.elsevier.com/myarticleservices/offprints). Authors requiring printed copies of
multiple articles may use Elsevier WebShop's 'Create Your Own Book' service to collate multiple articles
within a single cover (http://webshop.elsevier.com/myarticleservices/booklets).
Author orders
When your article is published, you can commemorate your publication with printed author
copies of the journal issue, customized full-color posters, extra offprints, and more. Please visit
http://webshop.elsevier.com to learn more.
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AUTHOR INQUIRIES
You can track your submitted article at https://www.elsevier.com/track-submission. You can track
your accepted article at https://www.elsevier.com/trackarticle. You are also welcome to contact
Customer Support via http://support.elsevier.com.
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